ArkBio Advances AK0406 in US Phase II Influenza Prevention Trial
Shanghai, China, October 13, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has announced that the U.S. Food and Drug...
Vaccines, Blood & Biologics
Immorta Bio Advances AI-Designed Senolytic Immunotherapy
Sarasota, Florida, U.S., October 13, 2026 Immorta Bio, Inc. has announced progress in its development of an artificial intelligence...
Celltrion Reports New ZYMFENTRA Data in Crohn’s Disease
Jersey City, New Jersey, USA, October 11, 2026 Celltrion USA has announced two new clinical analyses of ZYMFENTRA® (infliximab-dyyb),...
AbbVie Reports New SKYRIZI and RINVOQ IBD Data
North Chicago, Illinois, USA, October 11, 2026 AbbVie has announced new clinical and real-world evidence supporting SKYRIZI® (risankizumab-rzaa) and...
Genentech Reports One-Year Vamikibart Data in Eye Disease
South San Francisco, California, USA, October 10, 2026 Genentech, a member of the Roche Group, has announced new Phase...
Akeso Starts Phase 3 Cadonilimab Trial in Colon Cancer
Hong Kong, China, October 10, 2026 Akeso, Inc. has announced that the first patient has been dosed in a...
Vir Biotechnology’s VIR-5500 Gets FDA Fast Track Designation
San Francisco, California, USA, October 8, 2026 Vir Biotechnology, Inc. has announced that the U.S. Food and Drug Administration...
BioMarin Shares New Data on Rare Skeletal Disease Research
San Rafael, California, USA, October 9, 2026 BioMarin Pharmaceutical Inc. has announced new research findings across its rare disease...
Bristol Myers Squibb Reports ZENBEXUS Phase 3 Success
Princeton, New Jersey, USA, October 8, 2026 Bristol Myers Squibb (BMS) has announced positive Phase 3 results for ZENBEXUS™...
Johnson & Johnson Reports Two-Year ICOTYDE Psoriasis Data
Spring House, Pennsylvania, USA, October 9, 2026 Johnson & Johnson has announced new two-year clinical results for ICOTYDE® (icotrokinra),...